Author

Douglas Warner

eFFECTOR Therapeutics (United States)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Alexander Edward Dela Cruz DriloniD· 1 shared Corina AmoriD· 1 shared Elisa de StanchinaiD· 1 shared Ezra Y. RoseniD· 1 shared Fresia G. ParejaiD· 1 shared Gary Gene ChiangiD· 1 shared Guangli YangiD· 1 shared Hans‐Guido WendeliD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alexander Edward Dela Cruz DrilonORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer

Jacob A. Boyer, Ezra Y. Rosen, Malvika Sharma, Madeline A. Dorso, Nicholas Mai, Corina Amor, Jason Reiter, Ram Kannan, Sunyana Gadal, Jianing Xu, Matthew M. Miele, Zhuoning Li, Xiaoping Chen, Qing Chang, Fresia G. Pareja, , Neal X. Rosen

This paper identifies eIF4A as a key regulator of ER translation in breast cancer and shows that inhibiting eIF4A, either alone or with fulvestrant, suppresses ER expression and tumor growth in advanced ER+ breast cancer.

Proceedings of the National Academy of Sciences · Jul 21, 2025Peer-reviewedCancer Biology